Inmune Bio INMB Income Statement (2017-2026)

NASDAQ INMB
$2.16 -0.07 (-3.14%)
At close: Aug 20, 2026 · 4:00 PM EDT
1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
0.01M0.16M0.16M0.02M0.10M0.10M0.04M0.05M0.04M0.03M0.01M0.05M
Operating items
Research & Development (Quarter)
6.52M7.07M4.31M4.19M5.16M3.41M4.13M4.15M5.99M6.01M8.69M7.05M10.07M7.35M7.64M5.80M4.89M2.33M3.64M-0.80M
Selling, General & Administrative (Quarter)
2.52M2.12M2.33M2.21M2.38M2.33M2.33M2.31M2.59M2.40M2.34M2.81M2.22M2.11M2.32M2.25M2.55M3.15M2.17M2.28M
Other Operating Expenses (Quarter)
-0.42M-0.11M-0.09M-0.01M0.12M16.51M
Operating Expenses (Quarter)
9.04M9.19M6.64M6.40M7.54M5.74M6.46M6.46M8.57M8.41M11.03M9.87M12.29M9.47M9.96M24.57M7.43M5.47M5.81M1.48M
Operating Income (Quarter)
-9.02M-9.03M-6.48M-6.39M-7.44M-5.64M-6.42M-6.41M-8.53M-8.38M-11.02M-9.87M-12.29M-9.47M-9.90M-24.57M-7.43M-5.47M-5.81M-1.48M
EBIT (Quarter)
-9.02M-9.03M-6.48M-6.39M-7.44M-5.64M-6.42M-6.41M-8.53M-8.38M-11.02M-9.87M-12.29M-9.47M-9.90M-24.57M-7.43M-5.47M-5.81M-1.48M
Non-operating items
Interest & Investment Income (Quarter)
Other Non Operating Income (Quarter)
-0.01M0.17M
Non Operating Income (Quarter)
-0.44M-0.64M-0.42M-0.04M-0.03M0.12M0.19M0.25M0.17M0.11M0.96M0.21M0.41M0.20M
Net income details
EBT (Quarter)
-54.19M-9.47M-6.91M-6.85M-532.44M-6.50M-7.04M-7.04M-13.42M-9.26M-34.83M-20.52M-157.29M-10.50M-19.28M-24.72M-8.63M-6.02M-6.07M-3.09M
Profit After Tax (Quarter)
-9.53M-9.67M-6.90M-6.84M-7.72M-5.39M-6.54M-6.50M-8.56M-8.36M-11.03M-9.75M-12.42M-9.22M-9.77M-24.46M-6.47M-5.26M-5.41M-1.37M
Income from Continuing Operations (Quarter)
-54.19M-9.47M-6.91M-6.85M-532.44M-6.50M-7.04M-7.04M-13.42M-9.26M-34.83M-20.52M-157.29M-10.50M-19.28M-24.72M-8.63M-6.02M-6.07M-3.09M
Consolidated Net Income (Quarter)
-54.19M-9.47M-6.91M-6.85M-532.44M-6.50M-7.04M-7.04M-13.42M-9.26M-34.83M-20.52M-157.29M-10.50M-19.28M-24.72M-8.63M-6.02M-6.07M-3.09M
Income towards Parent Company (Quarter)
-54.19M-9.47M-6.91M-6.85M-532.44M-6.50M-7.04M-7.04M-13.42M-9.26M-34.83M-20.52M-157.29M-10.50M-19.28M-24.72M-8.63M-6.02M-6.07M-3.09M
Net Income towards Common Stockholders (Quarter)
-54.19M-9.47M-6.91M-6.85M-532.44M-6.50M-7.04M-7.04M-13.42M-9.26M-34.83M-20.52M-157.29M-10.50M-19.28M-24.72M-8.63M-6.02M-6.07M-3.09M
Additional items
EPS (Basic) (Quarter)
-3.13-0.59-0.39-0.38-29.67-0.36-0.39-0.39-0.75-0.52-1.93-1.06-7.79-0.53-0.86-1.06-0.32-0.24-0.23-0.12
EPS (Diluted) (Quarter)
-3.13-0.59-0.39-0.38-29.67-0.36-0.39-0.39-0.75-0.52-1.93-1.06-7.79-0.53-0.86-1.06-0.32-0.24-0.23-0.12
Shares Outstanding (Quarter)
17.33M16.13M17.87M17.95M17.95M17.93M17.95M17.95M18.01M17.98M18.03M19.31M20.19M19.94M22.50M23.30M26.59M24.76M26.59M26.72M
Shares Outstanding (Diluted) (Quarter)
17.33M16.13M17.87M17.95M17.95M17.93M17.95M17.95M18.01M17.98M18.03M19.31M20.19M19.94M22.50M23.30M26.59M24.76M26.59M26.72M
Shares Outstanding (Entity) (Quarter)
17.84M17.84M17.95M17.95M17.95M17.95M17.95M17.95M17.95M17.95M17.95M19.71M22.17M22.28M22.93M26.59M26.59M26.59M26.59M27.75M
EBITDA (Quarter)
-9.02M-9.03M-6.48M-6.39M-7.44M-5.64M-6.42M-6.41M-8.53M-8.38M-11.02M-9.87M-12.29M-9.47M-9.90M-24.57M-7.43M-5.47M-5.81M-1.48M
Interest Expenses (Quarter)
45.17M0.44M0.43M0.47M525.00M0.86M0.61M0.63M4.89M0.88M23.81M10.65M145.00M1.03M9.37M0.15M1.20M0.55M0.26M1.61M